Business Insider

Mylan to Acquire the Global Marketing Rights to a Once-monthly Glatiramer Acetate Product through an Investment and Partnership with Israeli Company Mapi Pharma

Once approved, this product could represent a significant milestone for patients with relapsing-remitting multiple sclerosis Mapi Pharma has completed an open-label Phase II clinical trial and is ...
Business Insider

Mylan To Buy Marketing Rights To Mapi's Glatiramer Acetate Product

(RTTNews) - Mylan N.V. (MYL) and Mapi Pharma Ltd. said that they will partner on the development and commercialization of GA Depot, a long-acting Glatiramer Acetate product. Mylan is acquiring global ...
Becker's Hospital Review

FDA approves Mylan’s generic version of Teva’s MS drug

Mylan on Tuesday earned Food and Drug Administration approval for its generic version of Teva’s multiple sclerosis drug Copaxone. 1. Mylan’s glatiramer acetate injection is intended to treat patients ...
Drug Store News

District Court ruling on Tecfidera patent opens door for Mylan's generic

Mylan is closer to offering a generic treatment for patients with relapsing forms of multiple sclerosis. The U.S. District Court for the Northern District of West Virginia on Thursday invalidated ...
Monthly Prescribing Reference

Medication Error Possible if Incompatible Autoinjector Used to Administer MS Drug

Senior patient talks about autoinjector with her doctor. Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis. The Food and Drug Administration (FDA) ...
Morningstar

ScinoPharm Secures U.S. FDA Approval for Glatiramer Acetate Injection for the Treatment of Multiple Sclerosis

TAINAN, Jan. 5, 2026 /PRNewswire/ -- ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) ...